Fund moves

AbbVie (ABBV): Bradley Foster & Sargent Inc reduced its stake -4,880 shares

Bradley Foster & Sargent Inc reduced its stake in AbbVie, per its Q1 2026 13F.

223K
Shares reported · -4,880 vs prior quarter
0.75%
Disclosed portfolio weight
$48.5M
Reported value
Holdings as of
Mar 31, 2026
Filed
May 15, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

  1. Feb 3, 2026Federal contract · $5K obligatedDepartment of Defense awarded AbbVie: $4.6K obligated to date
  2. Mar 5, 2026Federal contract · $3K obligatedDepartment of Defense awarded AbbVie: $3.4K obligated to date
  3. Mar 26, 20265% stakeThe Vanguard Group reported a passive stake (13G)
  4. Mar 27, 2026CongressDisclosed purchase of ABBV — reported range $15,001 - $50,000
  5. Apr 3, 2026Company filing · Form 8-K · ResultsReported its results
  6. Apr 23, 2026Government · Federal Register noticeKimberly Schaff Kiehl: Final Debarment Order
  7. Apr 29, 2026Company filing · Form 8-K · ResultsReported its results
  8. Apr 29, 20265% stakeVanguard Capital Management reported a passive stake (13G) of 7.5%
  9. May 5, 2026CongressDisclosed sale of ABBV — reported range $1,001 - $15,000

What came next

  1. May 18, 2026FDARecall: PRED MILD, prednisolone acetate ophthalmic suspension, USP, 0.12%, 10 mL, Sterile, Rx only, Allergen, Inc., an AbbVie company, North Chicago, IL 60064, Product…
  2. May 19, 2026Layoff notice · 2525 Dupont Drive Irvine CA 92612Layoff notice filed in CA: 85 employees
  3. May 20, 2026FDAFDA drug approval: Venclexta
  4. May 21, 2026FDAFDA drug approval: Linzess
  5. May 27, 2026FDAFDA drug approval: Decnupaz
  6. Jun 3, 2026Government · Federal Register noticeElite Laboratories, Inc. et al.; Withdrawal of Approval of 16 Abbreviated New Drug Applications
  7. Jun 8, 2026Government · Federal Register noticeDetermination That Protamine Sulfate (Protamine Sulfate) Intravenous; Solution, 50 Milligrams/5 Milliliters, and Other Drug Products Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness
  8. Jun 12, 2026FDAFDA drug approval: Skyrizi
  9. Jun 18, 2026Federal contract · $4K obligatedDepartment of Defense awarded AbbVie: $3.6K obligated to date
  10. Jun 26, 2026FDAFDA drug approval: Skyrizi
  11. Jun 26, 2026Government · Federal Register noticeDetermination That RECTIV (Nitroglycerin) Ointment, 0.4%, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness
  12. Jun 29, 2026Government · Federal Register noticeDetermination of Regulatory Review Period for Purposes of Patent Extension; VYALEV
  13. Jul 1, 2026Federal contract · $3K obligatedDepartment of Defense awarded AbbVie: $3.3K obligated to date
  14. Jul 6, 2026Company filing · Form 8-K · ResultsReported its results
  15. Jul 6, 2026Government · Federal Register noticeEndo Operations Limited, et al.; Withdrawal of Approval of 34 New Drug Applications
  16. Jul 7, 2026Government · Federal Register noticeCertain Antibody Drug Conjugates and Components Thereof and Products Containing the Same; Notice of a Commission Determination Not To Review an Initial Determination Terminating the Investigation; Termination of Investigation
  17. Jul 31, 2026Company filing · Form 8-K · ResultsReported its results
  18. Aug 14, 2026Insider · Their largest sale since 2023Officer sold ~$8.18M of ABBV shares in the open market
  19. Sep 1, 2026Government · Federal Register noticeDetermination That NAMENDA (Memantine Hydrochloride) Tablets, 5 Milligrams and 10 Milligrams, Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness
  20. Sep 2, 2026Government · Federal Register noticeDetermination That CARAFATE (Sucralfate) Oral Suspension, 1 Gram/10 Milliliters, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness
View the official recordSEC Form 13F-HR

How to read SEC Form 13F-HR

Form 13F is the quarterly report in which investment managers that oversee $100 million or more list the US-listed stocks and some other securities they held on the last day of the quarter.

Full guide: What is an SEC Form 13F?

What else is on file for AbbVie

For AbbVie, OQRO holds 3 insider filings (SEC Form 4 or Form 144), 1 Congress trade report and 3 fund holdings reports (13F) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its ABBV page.

How this filing works

Explore the data

Common questions

What does this filing report about AbbVie (ABBV) stock?

Bradley Foster & Sargent Inc reduced its stake in AbbVie, per its Q1 2026 13F. Now 223K shares, $48.5M reported value, 0.75% of disclosed portfolio.

When did it happen, and when was it made public?

Holdings as of: Mar 31, 2026. Filed: May 15, 2026.

Is this a trade made on a known date?

No. A holdings report is a picture of the portfolio on the last day of the quarter. It shows what was held on that day, not the day or the price at which anything was bought or sold.

Where does this information come from?

From the SEC Form 13F-HR, a public record. The link to the official record is on this page, and OQRO copies its figures without changing them.

What else has been disclosed about AbbVie recently?

For AbbVie, OQRO holds 3 insider filings (SEC Form 4 or Form 144), 1 Congress trade report and 3 fund holdings reports (13F) dated in the last 90 days. They are listed on the ABBV page.

Does this mean ABBV stock is a buy or a sell?

No. This page describes one public filing. A filing does not say why someone traded and is not a forecast, so OQRO gives no recommendation.

Is OQRO free?

Yes. Every page of OQRO is free with an account, which takes a minute with Google and needs no card. Only the AI assistant is paid.

Other disclosures at AbbVie

Everything OQRO holds on this company is on its ABBV page.

This is one filing. OQRO holds the rest

Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.

OQRO is free for everyone. No card, no trial

OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data